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Cellular and humoral immune responses to vaccmes of hepatitis B type and rabies were Inhibited by specific Inhibitors of cathepsin B. specific 
synthetic substrates of cathepsin B and anti-cathepsm B antibody. Therefore the lysosomal cathepsin B of antigen presentmg cells plays an essential 
role in processing of these antigens for presentation to MHC class II. One of the active sites of cathepsin B. VN2,, 122 shares highly homologous 
sequences with a part of the desetope. a binding domam of antigemc peptides, VN,: h2 of MHC class II, /3-cham. This evidence suggests that the 
peptides processed by the substrate speclficlty of cathepsm B exhibit a common affinity to bind with the desetope of MHC class II, P-cham. 
Cathepsin B: Antigen processing; MHC class II; HBsAg; Revls vaccine 
1. INTRODUCTION 
Knowledge on the structures and properties of in- 
tralysosomal proteases has been accumulated recently, 
especially on cysteine proteases, such as cathepsin B, H, 
L, J, S and N [11,12]. On the other hand, increased 
awareness of important physiological roles in the intra- 
cellular protein degradation process has been paralleled 
by the increased attention to the different functional 
shares of individual cathepsins. 
The determinant proteases responsible for individual 
protein degradation and processing appear to differ 
with different physiological purposes. Which lysosomal 
cathepsin is the determinant protease responsible for 
processing of specified antigens on the course of antigen 
presentation to MHC class II? T lymphocyte activation 
occurs only via interaction of antigen-specific clonally 
distributed T cell receptors (TCR) with structures on the 
surface of the antigen presenting cells (APC). The im- 
munogenic ligands to T cells must be presented as a 
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Abbwwmons. HBsAg. hepatitis B surface antigen; MHC-class II. 
major lustocompatibility complex class II; RV, rabies vaccine. Rx- 
PBMC, irradiated autologous peripheral mononuclear cell: APC, an- 
tigen presenting cells; E-64a. N-(L-3-trawls-ethoxycarbonyloxirane-2- 
carbonyl)-L-leucine-4-aminobutylamide; E-64d. N-(L-3-trlms-ethowy- 
carbonyloxirane-2-carbonyl)-L-leuclne-3-methylbutylamide~ CA-074. 
N-(L-3-frrm~-propylcarbamoyloxlrane-2-carbonyl)-L-isoleucyl-L-pro- 
line); Z-RR-MCA. benzyloxycarbonyl argmyl argmyl methylcouma- 
ryl amide. 
complex with major histocompatibility molecules class 
II (MHC class II) [ 1,2]. The processing of immunogenic 
fragments from the natural antigen is thought to be an 
intralysosomal event after endocytosis of antigens into 
macrophages, but the protease responsible for the anti- 
gen processing has not been determined. On the other 
hand, the primary structure and tertiary structure by 
X-ray crystallography of cathepsin B has been estab- 
lished by Katunuma et al. [l&19]. We investigated the 
protease responsible for the processing of hepatitis B 
vaccine (HBsAg) [3.4] and rabies vaccine [5] using vari- 
ous kinds of specific inhibitors of cysteine proteases, 
such as, E-64 [6.7]. an inhibitor for all members of the 
cysteine protease family and CA-074 [S], a specific in- 
hibitor of cathepsin B and also F(ab)’ of anti-cathepsin 
B antibody [9]. Herein, we report the mechanisms on 
antigen processing by cathepsin B and antigenic peptide 
presentation to MHC class II at the molecular level. 
2. MATERIALS AND METHODS 
Male BALBlc mice were obtamed from Clea Japan, Tokyo and 
were used at 8 to 10 weeks of age The ELISA kit for anti-HBs was 
purchased from Abbott Laboratones. North Chlcago. Yeast-derived 
recombmant hepatitis B surface antigen (subtype adr. HBsAg) was 
purchased from Kaketsuken Pharmaceutical Co.. Kumamoto, Japan 
For lmmumzation. HBsAg was emulslfied m alummum hydroxide gel. 
Rabies vaccine (RV), peptldes of rabies vaccme. ER,,, 14u: EECL- 
DALESTMTTKSVSFR derived from rabies glyco-protein and 
AP,,, 112 : ALTGGMELTRDPTVP [5.15,16] from rabies nuclear-pro- 
tem. and also human T-cell clones, namely 2C5 and B8. whtch respond 
speclfically to rabies vaccme were a gift from Dr. E. Cells. The autol- 
ogous peripheral blood mononuclear cells irradiated with 3.000 rd 
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(Rx-PBMC) was prepared as APC (antigen presentmg cells) Com- 
plete Freund’s adjuvant was from Dlfco Laboratories. Cysteme pro- 
tease Inhibitors: E-61a. E-64d. and CA-074 were a gift from Taisho 
Pharmaceutical Co.. Tokyo E-64a was dissolved m saline, and E-64d 
and CA-074 was m dimethylsulfo\lde at a concentration of 10 mg/ml. 
respectively, and diluted m saline at the indicated concentrations be- 
fore use. The specltic substrate for cathep\m B. Z-RR-MCA was 
purchased from the lnatltute for Protein Research. Peptide Inst. Inc.. 
Osaka [‘H]Thymldme was purchased from New England Nuclear. 
Boston, MA. RPM1 1640. metrlzamlde and heparin kvere purchased 
from Sigma Chemicals. St Louis. A series of synthetic peptldes, corre- 
sponding to antlgemc domaln of HBsAG (adr). SR,, :‘), SL,, gJ and 
FG 41 ,,I were synthesized by Applied Biosqstem Model A 431 peptlde 
syntheslzcr F(ab)’ of sprcitic antlbodq to cathepsm B. was prepared 
by the method of Komlnaml et al. [14]. 
Each group of this study conslsted of 10 male BALB/c mice. Mice 
were injected once mtraperltoneally with different doses of HBsAg 
(0.4 pg. 0 8 fig and 4 0 pug/mouse) with or without a cathepsm inhlbl- 
tor. E-64a. E-64d or CA-074 The cathepsm InhIbItor was InJected 
twice intraperltoneally at 1OO~glmouse before and after 2 h of Immu- 
mzatlon BALB/c mice were Injected m the base of the tall and hind 
footpads with 5 pg/mouse of rabies vaccine or 30 pg/mouse of sqn- 
thetic peptlde ER:,, z,,u In complete Freund’s adjuvant wlthlulthout 
300 fig/mouse of cysteme mhlbltors, such as E-6Ja. E-63d or CA-074 
3.3 A.s.wJ~ of prrrnurj’ crmlhodj~ productron fbr HBJ.@ m v,vo 
The amounts of IgG-class anti-HBrAg m the pooled mice sera on 
days 7, 10. 12, 14, 21 and 42 after immunization here titrated in 
triplicate using the ELISA Kit Results here presented as mean ? 1 
SD (mu/ml). 
At the 14th day after priming by HBsAg. aplenocytea (3 x lOh celld 
ml) of the primed BALB/c mice were prepared and incubated on a 
96-well culture plate wclth various concentrations of HBsAg or syn- 
thetic peptides with or wlthout cathepsln B Inhibitor (25pg/ml) for 72 
h m triplicate m RPMI 1640 medium supplemented with 3% mouse 
serum, ?-mercaptoethanol (5 x 10mh M), penicillin (100 U/ml). and 
streptomycin (100 pg/ml). The cultures \vere pulsed durmg the last 8 
h with 1 pCl/well of [‘Hlthymidme and harvested onto glass fiber 
filters. RadIoactivIty was quantified bq llquld scmtlllatlon counting 
and the results of the cell prohferatlon were expressed as counts per 
minute (cpm). The results arc presented as mean cpm ? 1 S D. Cell 
proliferation was considered significant when the ratio of the cpm 
obtained m the presence of antigen to that m the absence of antigen 
was 2 15. 
2 5. Cell prohfrru,r IV rr~ponw oJ‘B8 md 2 C5 clonr~ for rtrhws wwm 
or Jynrhetlc prprrdrs AP,,, ,_gl umi ER,,, 2yu re.\prctively m vrtro 
T cell clone ZC5 or B8 (5 x 10J cells/well) in complete medium 
(RPM1 1640 plu? 109 human AB serum) was incubated with rabies 
vaccme or synthetic peptide. ER,,, ?,,,) or AP,,, ,qi at concentrations 
rangmg from 0 1 pg/ml to 0.3 pglml, respectively. m the presence of 
5 x IO’ cells/~ell of RX-PBMC plus various concentrations (1.15. 2.5 
and 5 pg/ml) of cysteme protease mhlbitora E-64d. E-64a. or CA-074 
for 72 h at 37°C. m 5% CO- m a final volume of200pl/well in complete 
medium, and 1 pCl/well of [‘Hlthymldme were pulsed for the final 16 
h and the mcorporatlon of [‘Hlthymldme was assayed The Rx-PBMC 
were premcubated with various concentrations of rabies vaccme for 
I? h as a control. and after washmg with medium. ZC5 or B8 cells were 
mcubated filth the antigen-pulsed RX-PBMC in the presence of 5 
pg/ml of mhlbltor E-64d or CA-074. and then [‘Hlthymidme incorpo- 
ratlon has asaayed 
3. RESULTS AND DISCUSSION 
3.1. Cathepsin B znhihitors supprrss the primar), anti- 
body, rrsponse to HBsAg in viva 
A single immunization with HBsAg to BALB/c mice 
induced a sufficient increase in the anti-HBs titer (IgG) 
to 200 mIU/ml on the 10th day after immunization and 
reached a maximum level of 800 mIU/ml on the 2 1 st day 
as shown in Fig. 1 [IO], whereas the titers of antibody 
by priming with less than 1 .O ,ug of HBsAg were signif- 
icantly lower (below 100 mIU/ml throughout 21 days). 
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Fig 1. Effect of cathepsm B mhlbitors on productlon of primary antlbody for HBsAg in vi\o BALB/c mice were Immunized with 4 pg/head of 
HBsAg intraperitoneally Cathepsm B inhibitors were administered tfilce mtraperltoneally at 1 h before and after immumzation l , E-64a (ZOO 
pg/mouse): n . CA-074 (200 pug/mouse), ‘~1. control (saline): n, daily InJectIon of CA-074 (200 pg/mousc) for 14 days after prlmmg Anti-HBs IgG 
titers m sera were titrated by ELISA at the indicated time Data arc expressed as mean 2 S.D 
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Treatment of E-64a or CA-074 caused a marked sup- 
pression of anti-HBsAg production and delay in the 
response. Maximum suppression by the inhibitors was 
observed on the 14th day after immunization. That is, 
500 mIU/ml in the control and 250 mIU/ml by a single 
treatment with CA-074 or E-64a. Furthermore, daily 
treatment with CA-074 for 14 consecutive days after 
immunization caused strong suppression of the anti- 
body production to 120 mIU/ml level on the 14th day. 
3.2. Cathepsin B inhibitors suppress primary T cell sensi- 
tization arld also proliferative responses of primed 
splenocytes by rechallenge of whole vaccirze or the 
antigenic peptide of HBsAg 
BALB/c mice were primed with 4 ,uglmouse of 
HBsAg and then 14 days after priming, the primed 
splenocytes were rechallenged with HBsAg in vitro in 
the presence or absence of 5 ,ug/ml of cathepsin B inhib- 
itors and the proliferative response was assayed by 
[3H]thymidine incorporation. The primed splenocytes 
showed a proliferative response by rechallenge with 
HBsAg, while in the presence of cathepsin B inhibitors 
such as E-64a or CA-074, the responses were markedly 
suppressed to 30-50% of that without inhibitor as 
shown in Exp. 1 of Table I. Splenocytes primed by 
HBsAg in the presence of CA-074 or E-64a showed a 
very weak response, but also this proliferative response 
was further suppressed by administration of E-64a or 
CA-074 to 4045% of that without the inhibitor. 
The most susceptible bond in the HBsAg sequence 
[ 131 to cathepsin B [ 11,121 is considered to be the bond 
between 79th and 80th peptide, and this most suscepti- 
ble bond is practically cleaved by purified cathepsin B 
in vitro. The synthesized 16-mer peptide. SR,,_,, [14] of 
HBsAg, the extention peptide in the direction of the 
N-terminus before RR, showed the strongest prolifera- 
tive response to primed splenocytes as shown in Exp. 2 
of Table 1, and the other domain in the HBsAg molecule 
showed a much weaker response in the same system. 
The response by this active peptide was not inhibited by 
cathepsin B inhibitors. Therefore, it is possible to con- 
clude that the SR6a~,9 sequence is the most powerful 
antigenic peptide of HBsAg and the fragment is ex- 
pected to be naturally formed by limited proteolysis of 
cathepsin B in situ. 
3.3. Inhibitory effect of’ cathepsin B inhibitors. speciJic 
substrute of cathepsin B and F(ab)’ of anti-cathep- 
sitz B antibod), on the proliferative responses of 
human T cell clones +rith antigenic peptides 
Human T cell clones, 2C5 and B8 [5.15,16] in the 
presence of Rx-PBMC showed a high proliferative re- 
sponse to 0.2 pug/ml of rabies vaccine. The responses 
were suppressed by E-64d and CA-074 in a dose-de- 
pendent manner as shown in Fig. 2(a)-1 and (b)-1 . 
When Rx-PBMC prepulsed with rabies vaccine was 
used as the APC, this response was not suppressed by 
cathepsin B inhibitors as the dotted line shows. 2C5 and 
B8 in the presence of Rx-PBMC was also stimulated by 
ER 281 299 and AP,,,_,,,. respectively. However. the pro- 
Table 1 
Effect of cathepsm B inhibitors on prohferative response of prlmed splenocytes bq rechallenge of HBsAg or antlgemc peptldes of HBsAg 
In VIVO [‘H]Thymldme mcorporatlon into bplenocytes (cpm) 
sensitization with by in vitro rechallenge of: 
None HBsAg HBsAg + E-64a HBsAg + CA-074 
Exp. 1 None 143 f 48 412+ 57 2132 65 19oir 50 
(1) (2.9) (1.5) (1.4) 
HBsAg 440 k 64 4.092 * 540 2,112 * 660 I .980 f 360 
(1) (9.3) (4.8) (4.5) 
HBsAg + E-64a 214 + 58 550 f 124 481 f 143 410 -t 185 
(I) (2.3) (2.0) (1.7) 
HBsAg 183 + 41 5,475 i 439 1.336 + 328 1.841 f 210 
(1) (30) (7 3) (10) 
HBsAg + CA-074 113238 464 f 85 184k 23 206 ?r 58 
(1) (4.1) (1.6) 
None SR,, :q SL, L)J FG,, ,,I 
- CA-074 + CA-074 
Exp. 2 HBsAg 428 + 56 2,568 k 410 2,482 f 550 I .626 * 359 556 + 66 
(1) (6.0) (5.8) (3.7) (1.2) 
BALBlc mice were lmmumzed as described m Fig, 1. 14 days after Immumzation. 1 x 10’ cells of splenocytes were incubated for 72 h with 4 &ml 
of HBsAg and 1 &ml of cathepsin B mhlbltor. E-64a or CA-074. Cells were pulsed with 1 ~CI of [‘Hlthymidme for the last 12 h and [jH]thymidine 
mcorporatlons were assayed. Data are shown as mean + SD. cpm. SR, + SCPPI CPGYRWMCLRR. SL, 94: SCPPI CPGYRWMCLRRFI I 
FI FI LLLCLI FL. FG,, ,,:: FLLVLLDYQGMLPVCPLLPG. Each value indicates the mean + SD of 5 observations. P < 0.05: significant 
difference from control group (Stu&nt’.r t-test). 
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Ftg. 2. Inhrbttory effcts of E-6-ld and CA-073 on prohferatrve response of human T cell clones by rechallenge of rabtes vaccine or anttgemc pepttde. 
3 x 10’ cells of X5 clone were Incubated for 72 h with rabres vaccine ((a)-I. (b)-1) or synthetrc pcptrde. ER,,, :‘)‘, ((a)-?. (b)-2) m the presence of 
1 x 10’ cells of Rx-PBMC plus various concentratrons of cathepsm B mhrbrtors. E-63d or CA-071 E43d NCBS used m (a)-) and (a)-?. and CA-073 
was used m (b)-1 and (bj-7. (A A) Prepulsed Rx-PBMC + 5pg/mI ofmhrbrtor; (O-~-O) Rx-PBMC + anttgen + 1 75,&ml ofmhtbttor; (v==H) 
Rx-PBMC + antigen + 7.5 pug/ml of tnhlbrtor; (.---.) Rx-PBMC + antrgen + 5 ,~gjrnl of mhrbrtor. (7-1.) Rx-PBMC + antigen 
cpm 
xl o4 
2T 
p3 ml 
Fig. 3. lnhrbitton of T cell prohferatton by F(ab)’ of anti-cathepsm B 
antibody and specific substrate of cathepsm B, Z-RR-MCA. 3 x 10’ 
cells of X5 clone were incubated for 71 h with 1 x 10’ cells of Rx- 
PBMC and 0.2 pg/ml of rabres vaccine m the presence of vartous 
concentrations of F(ab)’ of anti-cathepsm B antibody or control IgG. 
Cells were pulsed with 1 &Xvell of [‘H]thymrdme for the last 12 h 
and harvested. 
liferative response by these antigenic peptides was not 
suppressed by cathepsin B inhibitors. E-64 and CA-074 
as shown in Fig. ‘(a)-2 and (b)-2. This response of the 
X5 clone to rabies vaccine was also suppressed by 
coincubation with F(ab)’ of cathepsin B-specific anti- 
body as shown in Fig. 3. Z-RR-MCA, a specific sub- 
strate of cathepsin B [17]. strongly suppressed the re- 
sponse, and MCA itself shows no effect. The same re- 
sults were obtained in these proliferative responses men- 
tioned above on the B8 clone (data not shown). It was 
reconfirmed that cathepsm B is the determinant pro- 
tease responsible for antigen processing of vaccines of 
HBsAg and rabies presented with MHC, class II. 
3.4. hllibitor~~ ejjkt of’ CA-074 arrd E-6& OII the prim- 
ing of mice irl viva ad recliullenge irl vitro n+tll 
rubies wccine or the untigenic peptides 
Splenocytes from mice primed with the rabies vaccine 
showed a high proliferative response to rechallenge with 
the rabies vaccine and also to antigenic peptide ER,,, _z99 
in vitro. Since the priming with rabies vaccine in the 
presence of CA-074 or E-64d was suppressed strongly, 
the splenocyte response to the rechallenge with the vac- 
3x3 
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Fig. 4. Inhibitory effect of E-64d and CA-074 on priming of BALB/c mice with rabies vaccine. Splenocytes from BALB/c mice primed with rabies 
vaccine m vl\o m the presence or absence of E-64d or CA-074 were incubated with the vaccme or ER :*, 299 and the prohferative responses were 
assayed. 
tine or ER?8,_2YV was suppressed as shown in Fig. 4. 
However. when mice were primed with ER2R, 141) with 
adjuvant in the presence of CA-074 or E-64d, the prim- 
ing was not suppressed by these inhibitors (data not 
shown). These findings indicate that cathepsin B inhib- 
itors cannot interfere with the binding of the already 
processed peptides to MHC class II and any other proc- 
esses of the immune responses except the proteolytic 
processing of antigens. 
3.5. Antigenic peptides processed by, limited pvoteolJ)sis 
of cathepsin B shove comnwl @nit)- to biud \t,ith 
MHC class II 
Since cathepsin B shows substrate specificity for par- 
ticular susceptible sequences. the processed peptides by 
cathepsin B contain a particular common sequence in 
the ragged C-terminus sequences, such as -XYRR etc. 
It is possible to speculate that the fragments formed by 
selective proteolysis of cathepsin B can bind commonly 
with the desetope of MHC class II P-chain. The syn- 
thetic peptides, MCLRR and YRWMCLRR, ragged 
C-end sequences of the antigenic peptide of HBsAg, 
SR 64-79, inhibited the immune responses to rabies vac- 
cine. When the 2C5 clone with Rx-PBMC was immu- 
nized with rabies vaccine in the presence of MCLRR or 
YRWMCLRR, the proliferative response of [3H]thy- 
midin incorporation was suppressed to 75% or 60% of 
that in the absence of these peptides, respectively. It is 
possible to speculate that these peptides inhibit antigen 
processing by cathepsin B and also inhibit the binding 
of processed peptides to the desetope of MHC class II. 
One of the active sites of cathepsin B [l&19], VN,,, 123. 
-VANSWNT-, shows high homology with part of the 
binding domain (desetope) of MHC class II, /?- chain, 
VN 57 63% -VAESWNS- [20]. Furthermore, within the 
common homologous sequences, alanine and asparag- 
ine are the same amino acids on cathepsin B and MHC 
class II, while the alanine and the asparagine in the same 
active domain of the other cathepsins are commonly 
substituted by lysine and glycine, respectively, as shown 
in Fig. 5. This is one of the important reasons why only 
the cathepsin B specifically makes antigenic peptides to 
bind to MHC class II. 
Here, we propose the hypothesis as illustrated in Fig. 
6. The C-terminal domain sequences in antigenic pep- 
tides showing common affinity for MHC class II are 
selected by the substrate specificity of cathepsin B. The 
sequences of antigenic peptides isolated from MHC 
class II molecules has been reported [23-251. The major- 
ity of these peptides contain affinity sequences for 
cathepsin B, although some of the peptides reported do 
not contain the affinity sequences for cathepsin B. 
Many explanations for this problem may be possible. 
Some additional proteolytic modifications may follow 
during the antigen presentation. or other lysosomal pro- 
teases than cathepsin B may participate in some other 
antigen processing, and the antigenic peptides are affin- 
ity-linked to another domain of the desetope of MHC 
class II. We conclude that the antigenic fragments of 
HBsAg and rabies vaccines are processed by cathepsin 
B and show common affinity to bind to the desetope of 
MHC class II, /?-chain. 
A~X_no~~,let/~rnfel11J We thank Dr. Esteban Cells for providing us with 
human T cell clones, ZC5 and BS, and Miss M. Kanbe for expert 
secretarlal assistance. 
Fig. 5. One of active sites of cathepsm B shares homology with a part 
of antigenic peptide bindmg domain (desetope) of MHC class II. 
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> 
MHC class II 
Fig. 6. Hypothesis on the processing and presentation mechanisms of antlgenic peptide by cathepsm B (by N. Katunuma) 
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